SCHEMBL2647405

SCHEMBL2647405

Clc1cc(-c2cccs2)c(Cl)nn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
NPC1 O15118 4/20 0.41
RAB9A P51151 4/20 0.41
KDM4E B2RXH2 4/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
ADORA2A P29274 2/20 0.39
ADORA1 P30542 2/20 0.39
ATM Q13315 1/20 0.39
TDO2 P48775 1/20 0.39
TDP1 Q9NUW8 3/20 0.38
MAPT P10636 2/20 0.38
HPGD P15428 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
RPS6KB2 Q9UBS0 2/20 0.37
HSD17B10 Q99714 2/20 0.37
EPHX2 P34913 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1623072 0.70 ADORA2A (0.57) ALDH1A1KDM4EL3MBTL1SMN1; SMN2ADORA2A
SCHEMBL6280818 0.70 KDM4E (0.48) ALDH1A1NPC1RAB9AKDM4EL3MBTL1
SCHEMBL1781624 0.69 MAPT (0.50) ALDH1A1NPC1RAB9AKDM4EL3MBTL1
SCHEMBL5026243 0.68 KDM4E (0.48) ALDH1A1NPC1RAB9AKDM4EL3MBTL1
SCHEMBL527009 0.68 CYP2A6 (0.43) ALDH1A1NPC1RAB9AKDM4EL3MBTL1
SCHEMBL11111178 0.68 AHR (0.46) ALDH1A1NPC1RAB9AKDM4EL3MBTL1
SCHEMBL30041839 0.68 CYP2A6 (0.43) ALDH1A1NPC1RAB9AKDM4EL3MBTL1
SCHEMBL13977912 0.68 KDM4E (0.52) ALDH1A1NPC1RAB9AKDM4EL3MBTL1
SCHEMBL10836135 0.68 RAB9A (0.46) ALDH1A1NPC1RAB9AKDM4EL3MBTL1
SCHEMBL2646929 0.67 CASP1 (0.41) ALDH1A1NPC1RAB9ASMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6828322-B2 Substituted 1,2, 4-triazolo(4,3-b)pyridazine derivatives; anxiolytic; anticonvulsant; antimigraine MERCK SHARP & DOHME LTD. 2004-12-07 US disclosed
US-20040063714-A1 Triazolo-pyridazine derivatives as ligands for GABA receptors CARLING WILLIAM ROBERT (GB) 2004-04-01 US disclosed
US-6579875-B1 Treatment of anxiety and convulsions; 7-cyclobutyl-3-(2,6-difluorophenyl)-6-(2-methyl-2H-1,2,4-triazol-3 -ylmethyoxy)-1,2,4-triazolo(4,3-b) pyridazine MERCK SHARP & DOHME LIMITED 2003-06-17 US disclosed
CN-1110498-C Triazolo-pyridazine derivatives as ligands for GABA receptors MERCK SHARP & DOHME (GB) 2003-06-04 CN disclosed
CN-1288465-A Triazolo-pyridazine derivatives as ligands for GABA receptors MERCK SHARP & DOHME (GB) 2001-03-21 CN disclosed
EP-1049696-A1 TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LTD. (GB) 2000-11-08 EP disclosed
WO-1999037644-A1 TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 1999-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063714-A1 Triazolo-pyridazine derivatives as ligands for GABA receptors GABRA3, GABBR1, GABRA2 ALDH1A1 1373/4885NPC1 3613/4885RAB9A 2820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.